Reclaim your health through regenerative medicine

Company information

Company Overview
Company name:
Innovacell AG
Head office:
Mitterweg 24, 6020 Innsbruck, Austria
Founded in:
2000 as Innovacell Biotechnologie GmbH
Number of employees:

Reclaim your health through regenerative medicine

Board of directors

Dr. Ekkehart Steinhuber


Dr. Ekkehart Steinhuber has been CEO of Innovacell AG since 2007. Dr. Steinhuber has extensive operational management experience from 25 years in the pharmaceutical division of Sandoz. As a board member, he was responsible for production, development, logistics and quality assurance as well as head of sales companies in Europe, the Far East and Africa – most recently as CEO of the Sandoz subsidiary in Hungary. Dr. Steinhuber studied social and economic sciences at the Universities of Innsbruck and Vienna and graduated with a doctorate.

Dr. Rainer Marksteiner

Board member

Dr. Rainer Marksteiner is co-founder and CSO of Innovacell AG. Since February 2002, Dr. Marksteiner worked as a scientific director in the field of research and product development in the company. Before that, he was a research assistant at the Institute for Biochemical Pharmacology at the University of Innsbruck and at the Dermatology Clinic Innsbruck. Dr. Marksteiner completed his degree study program in microbiology at the Leopold-Franzens-Universität Innsbruck with distinction, and in 1999 he obtained his doctorate in natural sciences with distinction. He has written numerous scientific publications in the field of cell biology.

Reclaim your health through regenerative medicine

Supervisory board

Dr. Gregor Trummer

Chairman of the Supervisory Board

Gregor Trummer is working as an attorney in Vienna and is a partner of the law firm of Trummer Thomas Rechtsanwälte GmbH with a focus on M & A. He is a graduate of the Paris Lodron University in Salzburg and the McGeorge School of Law in California, from which he obtained a Master of Laws degree in Transnational Business Practice. He then went on to acquire experience in the legal practice of a renowned law firm in San Francisco, California. Besides practicing as an attorney, he managed the Austrian representative office of the German Private Equity practice of HQ Equita in Vienna for many years. Gregor Trummer was and still is a member of numerous supervisory boards of major industrial enterprises in Austria.

Dr. Alexander Thomas

Supervisory Board

Alexander Thomas is an Austrian citizen who grew up, inter alia, in Pakistan and in Japan. He is a graduate of the University of Vienna law school and was practicing as an attorney in an international business firm in New York with a focus on international business law and M & A. He is a founding partner of Trummer Thomas Rechtsanwälte GmbH in Vienna. He holds numerous supervisory board mandates of renowned Austrian corporations and is also a board member of various private foundations.

Andrew Laurence Fleury, B.A.,M.A.

Supervisory Board

Originally from the San Francisco Bay Area, Andrew Fleury is a Vice President at CJ PARTNERS in Tokyo, one of Japan’s leading regenerative medicine consulting firms. He has extensive experience assisting foreign Biotechs developing cell therapies across a variety of indication areas with their clinical and commercial development in Japan. He holds a B.A. from Cornell University and an M.A. from Stanford University. In addition to Japan, Andrew has also spent substantial time in Hong Kong and Beijing.

Reclaim your health through regenerative medicine

What we do

Innovacell is a biotechnology company focused on developing, producing and marketing cell therapies for treating fecal and urinary incontinence. Technologies for isolating, multiplying, using and delivering muscle cells have been developed. Associated patents have already been granted or their applications filed.

Innovacell works according to the rules of “Good Laboratory Practice” (GLP), “Good Manufacturing Practice” (GMP) and “Good Clinical Practice” (GCP). These guidelines ensure that internationally recognized quality standards are met while developing, manufacturing, processing, packaging and storing pharmaceuticals and that customers and patients receive products of the highest quality.

Innovacell is one of the largest producers of autologous (endogenous) in vitro multiplied cells in Europe. Capacity is between 500 and 5,000 units per year, depending on the cell type.

Automation of manufacturing processes is in development. There are two main objectives:

  1. Capacity required in the commercialization phase shall be built up step by step (scale-up).
  2. This capacity shall be divided between five production plants, two in the EU, two in the USA and one in Japan, using a decentralized manufacturing and distribution model (scale-out).

Innovacell has approval to manufacture cell therapy test material for clinical studies. This includes currently the following cell types: autologous skeletal muscle cells, skin fibroblasts, and hair follicle cells.

Innovacell aims to market the products it has developed in the five key European countries (Germany, France, Italy, Spain and the United Kingdom) as well as in Japan and the USA. The goal is to become a global leader in the field of regenerative medicine with a focus on innovative, personalized cell therapies.

Reclaim your health through regenerative medicine


Innovacell is an equity funded company. The potential of innovative cell therapy, results obtained so far and further development steps all underline the quality of the work accomplished and have convinced both venture capitalists and other investors to support Innovacell.

Since the company’s founding in 2000, the Innovacell management team has been able to raise substantial funds to develop cell therapies in Europe. Furthermore, since 2019, the company has also been supported by Japanese investors in order to advance clinical development for the Asian region, especially Japan.

Innovacell’s operations and clinical development programs are funded by the following highly committed investors with extensive pharmaceutical experience:

  • Ci:z Investment LLP, Japan
  • Eagle Fund SP1 LLP, Japan
  • ID Pharma Group Co., Ltd., Japan
  • Peppermint Grove Ltd., Hong Kong
  • Private investors, Austria, Japan, Taiwan, USA

Working at Innovacell

Become part of our team!

Would you like to contribute to developing and approving a new generation of medicines and play a decisive role in producing new products? Is a positive, collegial working atmosphere important to you? Do you want to take responsibility? Then apply today!